Target | Neighbor | ANOVA p value |
CD8+T cells | CD8+T cells | 0.00097 |
T cells | DC | 0.0048 |
MΦ | DC | 0.0072 |
DNT cells | Tregs | 0.018 |
B cells | DC PDL1+ | 0.04 |
CD4+T cells | CD8+T cells | 0.04 |
HMWCK-PDL1+ | CD8+T cells | 0.046 |
T cells | MΦ | 0.056 |
DNT cells | CD8+T cells | 0.06 |
T cells | DC PDL1+ | 0.081 |
HMWCK-PDL1+ | Tregs | 0.095 |
CD8+T cells | HMWCK-PDL1+ | 0.1 |
MΦ | DC PDL1+ | 0.11 |
HMWCK+PDL1- | CD8+T cells | 0.11 |
CD4+T cells | CD4+T cells | 0.14 |
Tregs | CD8+T cells | 0.16 |
HMWCK-PDL1+ | CD4+T cells | 0.16 |
B cells | DC | 0.17 |
CD4+T cells | HMWCK-PDL1+ | 0.18 |
DNT cells | HMWCK-PDL1+ | 0.22 |
HDRBT, high dose-rate brachytherapy; PCa, prostate cancer.